Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has taken a strategic step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI marks the initial phase of negotiations toward a definitive agreement that would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3), a key immune checkpoint. This move could position Onco at the forefront of next-generation cancer immunotherapy, particularly by combining LAG-3 inhibition with its existing DNA damage response (DDR) expertise.
LAG-3 is an immune checkpoint receptor that suppresses T-cell activity, and its inhibition has emerged as a promising strategy in cancer treatment. Currently approved LAG-3 therapies are monoclonal antibodies administered intravenously, but Ifowonco is developing orally available small-molecule inhibitors, which could offer significant advantages in terms of patient convenience and potentially different pharmacokinetics. The proposed collaboration aims to leverage Onco's strengths in DDR therapeutics, translational oncology, and clinical development to evaluate the LAG-3 program both independently and in combination with DDR-based approaches, including Onco's ONC010 program.
The rationale behind combining DDR inhibition with LAG-3 blockade lies in the potential to enhance anti-tumour immune responses across multiple solid tumour indications. DDR inhibitors, such as PARP inhibitors, have been shown to increase immunogenicity of tumours by promoting DNA damage and activating innate immune pathways. By adding LAG-3 blockade, which removes a brake on T-cell activation, the combination could lead to a more robust and durable immune response. This hypothesis aligns with the growing interest in combining immune checkpoint inhibitors with other therapeutic modalities to overcome resistance and improve outcomes.
Thomas O'Shaughnessy, CEO of Onco-Innovations, expressed optimism about the potential agreement, stating that it could position the company “at the intersection of precision oncology and next-generation cancer immunotherapy.” This sentiment underscores the strategic importance of the move as Onco seeks to diversify its pipeline beyond its current focus on DDR-based therapeutics. The company has secured an exclusive worldwide license to patented technology targeting solid tumours, and adding an oral LAG-3 inhibitor could broaden its reach in the immuno-oncology space.
The LOI is a preliminary step, and the execution of a definitive agreement is subject to further negotiations and due diligence. However, the announcement signals Onco's intent to expand its capabilities in immunotherapy, a field that has seen rapid growth and significant investment. The potential combination of DDR and LAG-3 inhibition could address unmet medical needs in cancers that are resistant to current immunotherapies, offering new hope for patients.
Investors and industry observers will be watching closely as Onco and Ifowonco proceed with negotiations. The success of this collaboration could not only enhance Onco's portfolio but also contribute to the broader understanding of how to optimize cancer treatment regimens. As the companies evaluate the LAG-3 program, preclinical findings will be crucial in determining the path forward, particularly regarding its use alongside DDR-based therapies.
For more information on Onco-Innovations and its pipeline, visit the company's newsroom at https://ibn.fm/ONNVF. The full press release can be accessed at https://ibn.fm/E63Ne.
